Clostridioides difficile infection in the allogeneic hematopoietic cell transplant recipient.
Clostridioides difficile infection
allogeneic hematopoietic cell transplantation
fecal microbiota transplantation
recurrent Clostridioides difficile infection
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
09
09
2023
received:
10
08
2023
accepted:
14
09
2023
medline:
11
12
2023
pubmed:
3
10
2023
entrez:
3
10
2023
Statut:
ppublish
Résumé
Clostridioides difficile (CD) is one of the most important causes of diarrhea in hospitalized patients, in particular those who undergo an allogeneic hematopoietic cell transplant (allo-HCT) and who are more at risk of developing a CD infection (CDI) due to frequent hospitalizations, iatrogenic immunosuppression, and prolonged antibiotic cycles. CDI may represent a severe condition in allo-HCT patients, increasing the length of hospitalization, influencing the intestinal microbiome with a bidirectional association with graft-versus-host disease, and leading to unfavorable outcomes, including death. The diagnosis of CDI requires the exclusion of other probable causes of diarrhea in HCT patients and is based on highly sensitive and highly specific tests to distinguish colonization from infection. In adult patients, fidaxomicin is recommended as first-line, with oral vancomycin as an alternative agent. Bezlotoxumab may be used to reduce the risk of recurrence. In pediatric patients, vancomycin and metronidazole are still suggested as first-line therapy, but fidaxomicin will probably become standard in pediatrics in the near future. Because of insufficient safety data, fecal microbiota transplantation is not routinely recommended in HCT in spite of promising results for the management of recurrences in other populations.
Substances chimiques
Vancomycin
6Q205EH1VU
Fidaxomicin
Z5N076G8YQ
Anti-Bacterial Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14159Subventions
Organisme : Italian Ministry of Health
ID : Ricerca Corrente: RC 2022 Linea 1
Informations de copyright
© 2023 The Authors. Transplant Infectious Disease published by Wiley Periodicals LLC.
Références
Khanna S, Pardi DS. Clostridium difficile Infection: New Insights Into Management. Mayo Clin Proc. 2012;87(11):1106-1117.
Obeid KM, Sapkota S, Cao Q, et al. Early Clostridioides difficile infection characterizations, risks, and outcomes in allogeneic hematopoietic stem cell and solid organ transplant recipients. Transpl Infect Dis. 2022;24(1):e13720. Available from: https://onlinelibrary.wiley.com/doi/10.1111/tid.13720
Aslam S, Musher DM. An Update on Diagnosis, Treatment, and Prevention of Clostridium difficile-Associated Disease. Gastroenterol Clin North Am. 2006;35(2):315-335.
Dulęba K, Pawłowska M, Wietlicka-Piszcz M. Clostridium difficile infection in children hospitalized due to diarrhea. Eur J Clin Microbiol Infect Dis. 2014;33(2):201-209.
Van Prehn J, Reigadas E, Vogelzang EH, et al. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect. 2021;27:S1-S21.
Johnson S, Lavergne V, Skinner AM, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021;73(5):e1029-e1044.
Kelly CR, Fischer M, Allegretti JR, et al. ACG clinical guidelines: prevention, diagnosis, and treatment of clostridioides difficile infections. Am J Gastroenterol. 2021;116(6):1124-1147.
Alonso CD, Maron G, Kamboj M, et al. American Society for Transplantation and Cellular Therapy Series: #5-Management of Clostridioides difficile infection in hematopoietic cell transplant recipients. Transplant Cell Ther. 2022;28(5):225-232.
Diorio C, Robinson PD, Ammann RA, et al. Guideline for the management of Clostridium Difficile infection in children and adolescents with cancer and pediatric hematopoietic stem-cell transplantation recipients. J Clin Oncol. 2018;36(31):3162-3171.
Rizzatti G, Ianiro G, Gasbarrini A. Antibiotic and modulation of microbiota: a new paradigm? J Clin Gastroenterol. 2018;52(1):S74-S77.
Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis. 1993;17(1):109-113.
Willems L, Porcher R, Lafaurie M, et al. Clostridium difficile infection after allogeneic hematopoietic stem cell transplantation: incidence, risk factors, and outcome. Biol Blood Marrow Transplant. 2012;18(8):1295-1301.
Alonso CD, Braun DA, Patel I, et al. A multicenter, retrospective, case-cohort study of the epidemiology and risk factors for Clostridium difficile infection among cord blood transplant recipients. Transpl Infect Dis. 2017;19(4):e12728.
Misch EA, Safdar N. Clostridioides difficile Infection in the Stem cell transplant and hematologic malignancy population. Infect Dis Clin North Am. 2019;33(2):447-466.
Lavallée C, Labbé AC, Talbot JD, et al. Risk factors for the development of Clostridium difficile infection in adult allogeneic hematopoietic stem cell transplant recipients: A single-center study in Québec, Canada. Transpl Infect Dis. 2017;19(1):e12648.
Hosokawa K, Takami A, Tsuji M, et al. Relative incidences and outcomes of Clostridium difficile infection following transplantation of unrelated cord blood, unrelated bone marrow, and related peripheral blood in adult patients: a single institute study. Transpl Infect Dis. 2014;16(3):412-420.
Selvey LA, Slimings C, Joske DJL, Riley TV. Clostridium difficile infections amongst patients with haematological malignancies: a data linkage study. PLOS ONE. 2016;11(6):e0157839.
Trifilio SM, Pi J, Mehta J. Changing epidemiology of clostridium difficile-associated disease during stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(3):405-409.
Chakrabarti S, Lees A, Jones S, Milligan D. Clostridium difficile infection in allogeneic stem cell transplant recipients is associated with severe graft-versus-host disease and non-relapse mortality. Bone Marrow Transplant. 2000;26(8):871-876.
Mani S, Rybicki L, Jagadeesh D, Mossad SB. Risk factors for recurrent Clostridium difficile infection in allogeneic hematopoietic cell transplant recipients. Bone Marrow Transplant. 2016;51(5):713-717.
Chang K, Kreuziger LMB, Angell K, Young JA, Ustun C. Recurrence of Clostridium difficile infection after total colectomy in an allogeneic stem cell transplant patient. Bone Marrow Transplant. 2012;47(4):610-611.
Alonso CD, Treadway SB, Hanna DB, et al. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2012;54(8):1053-1063.
Dubberke ER, Reske KA, Olsen MA, et al. Risk for Clostridium difficile infection after allogeneic hematopoietic cell transplant remains elevated in the postengraftment period. Transplant Direct. 2017;3(4):e145.
Dutta D, Jafri F, Stuhr D, Knoll BM, Lim SH. A contemporary review of Clostridioides difficile infections in patients with haematologic diseases. J Intern Med. 2021;289(3):293-308.
Luo Y, Zhang S, Shang H, Cui W, Wang Q, Zhu B. Prevalence of Clostridium difficile infection in the hematopoietic transplantation setting: update of systematic review and meta-analysis. Front Cell Infect Microbiol. 2022;12:801475.
Rosignoli C, Petruzzellis G, Radici V, et al. Risk Factors and Outcome of C. difficile Infection after hematopoietic stem cell transplantation. J Clin Med. 2020;9(11):3673.
Weber S, Scheich S, Magh A, et al. Impact of Clostridioides difficile infection on the outcome of patients receiving a hematopoietic stem cell transplantation. Int J Infect Dis. 2020;99:428-436.
Pant C, Deshpande A, Gilroy R, Olyaee M, Donskey CJ. Rising incidence of Clostridium difficile related discharges among hospitalized children in the United States. Infect Control Hosp Epidemiol. 2016;37(1):104-106.
Kim J, Shaklee JF, Smathers S, et al. Risk factors and outcomes associated with severe Clostridium difficile infection in children. Pediatr Infect Dis J. 2012;31(2):134-138.
De Blank P, Zaoutis T, Fisher B, Troxel A, Kim J, Aplenc R. Trends in Clostridium difficile infection and risk factors for hospital acquisition of clostridium difficile among children with cancer. J Pediatr. 2013;163(3):699-705.e1.
Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol. 1995;16(8):459-477.
Palmore TN, Sohn S, Malak SF, Eagan J, Sepkowitz KA. Risk factors for acquisition of Clostridium difficile -associated diarrhea among outpatients at a cancer hospital. Infect Control Hosp Epidemiol. 2005;26(8):680-684.
Spruit JL, Knight T, Sweeney C, Salimnia H, Savaşan S. Clostridium difficile infection in a children's hospital with specific patterns among pediatric oncology and hematopoietic stem cell transplantation populations. Pediatr Hematol Oncol. 2020;37(3):211-222.
Nicholson MR, Osgood CL, Acra SA, Edwards KM. Clostridium difficile infection in the pediatric transplant patient. Pediatr Transplant. 2015;19(7):792-798.
Kamboj M, Xiao K, Kaltsas A, et al. Clostridium Difficile infection after allogeneic hematopoietic stem cell transplant: strain diversity and outcomes associated with NAP1/027. Biol Blood Marrow Transplant. 2014;20(10):1626-1633.
Salamonowicz M, Ociepa T, Frączkiewicz J, et al. Incidence, course, and outcome of Clostridium difficile infection in children with hematological malignancies or undergoing hematopoietic stem cell transplantation. Eur J Clin Microbiol Infect Dis. 2018;37(9):1805-1812.
Alrugaib T, Alsultan A, Elbashir E, Albdah B, Alharbi M, Essa MF. Antimicrobial prophylaxis and the rate of blood stream infections and Clostridioides difficile in pediatric stem cell transplantation: A single-center retrospective study. Pediatr Transplant. 2023;27(1):e14375. Available from: https://onlinelibrary.wiley.com/doi/10.1111/petr.14375
Ramanathan M, Kim S, He N, et al. The incidence and impact of Clostridioides difficile infection on transplant outcomes in acute leukemia and MDS after allogeneic hematopoietic cell transplant-a CIBMTR study. Bone Marrow Transplant. 2023;58(4):360-366.
Willis DN, Huang FS, Elward AM, et al. Clostridioides difficile Infections in inpatient pediatric oncology patients: A cohort study evaluating risk factors and associated outcomes. J Pediatr Infect Dis Soc. 2021;10(3):302-308.
Alexander S, Fisher BT, Gaur AH, et al. Effect of levofloxacin prophylaxis on bacteremia in children with acute leukemia or undergoing hematopoietic stem cell transplantation: a randomized clinical trial. JAMA. 2018;320(10):995.
Alonso CD, Dufresne SF, Hanna DB, et al. Clostridium difficile Infection after adult autologous stem cell transplantation: a multicenter study of epidemiology and risk factors. Biol Blood Marrow Transplant. 2013;19(10):1502-1508.
Salamonowicz M, Ociepa T, Frączkiewicz J, et al. Incidence, course, and outcome of Clostridium difficile infection in children with hematological malignancies or undergoing hematopoietic stem cell transplantation. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2018;37(9):1805-1812.
Haeusler GM, Lehrnbecher T, Agyeman PKA, et al. Clostridioides difficile infection in paediatric patients with cancer and haematopoietic stem cell transplant recipients. Eur J Cancer. 2022;171:1-9.
Barbar R, Hayden R, Sun Y, Tang L, Hakim H. Epidemiologic and clinical characteristics of Clostridioides difficile infections in hospitalized and outpatient pediatric oncology and hematopoietic stem cell transplant patients. Pediatr Infect Dis J. 2021;40(7):655-662.
Nicholson MR, Thomsen IP, Slaughter JC, Creech CB, Edwards KM. Novel risk factors for recurrent clostridium difficile infection in children. J Pediatr Gastroenterol Nutr. 2015;60(1):18-22.
Madden GR, Poulter MD, Sifri CD. Diagnostic stewardship and the 2017 update of the IDSA-SHEA Clinical Practice Guidelines for Clostridium difficile Infection. Diagnosis. 2018;5(3):119-125.
McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in adults and children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1-e48.
Zar FA, Bakkanagari SR, Moorthi KMLST, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45(3):302-307.
Belmares J, Gerding DN, Parada JP, Miskevics S, Weaver F, Johnson S. Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J Infect. 2007;55(6):495-501.
Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: Update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20:1-26.
Jain T, Croswell C, Urday-Cornejo V, et al. Clostridium Difficile colonization in hematopoietic stem cell transplant recipients: a prospective study of the epidemiology and outcomes involving toxigenic and nontoxigenic strains. Biol Blood Marrow Transplant. 2016;22(1):157-163.
Ford CD, Lopansri BK, Coombs J, Webb BJ, Asch J, Hoda D. Are Clostridioides difficile infections being overdiagnosed in hematopoietic stem cell transplant recipients? Transpl Infect Dis. 2020;22(4):e13279. Available from: https://onlinelibrary.wiley.com/doi/10.1111/tid.13279
Nomura K, Fujimoto Y, Yamashita M, et al. Absence of pseudomembranes in Clostridium difficile -associated diarrhea in patients using immunosuppression agents. Scand J Gastroenterol. 2009;44(1):74-78.
Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus Vancomycin for Clostridium difficile Infection. N Engl J Med. 2011;364(5):422-431.
Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12(4):281-289.
Louie TJ, Cannon K, Byrne B, et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and Reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis. 2012;55(2):S132-S142.
Ajami NJ, Cope JL, Wong MC, Petrosino JF, Chesnel L. Impact of oral fidaxomicin administration on the intestinal microbiota and susceptibility to Clostridium difficile colonization in mice. Antimicrob Agents Chemother. 2018;62(5):e02112-e02117.
Yamaguchi T, Konishi H, Aoki K, Ishii Y, Chono K, Tateda K. The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin. J Infect Chemother. 2020;26(5):483-491.
Crook DW, Walker AS, Kean Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile Infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis. 2012;55(2):S93-S103.
Johnson S, Louie TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: Results from two multinational, randomized, controlled trials. Clin Infect Dis. 2014;59(3):345-354.
Metan G, Türe Z, Kaynar L, et al. Tigecycline for the treatment of Clostridium difficile infection refractory to metronidazole in haematopoietic stem cell transplant recipients. J Chemother. 2015;27(6):354-357.
Freeman J, Vernon J, Morris K, et al. Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes. Clin Microbiol Infect. 2015;21(3):248.e9-248.e16.
Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017;376(4):305-317.
Gerding DN, Kelly CP, Rahav G, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection in patients at increased risk for recurrence. Clin Infect Dis. 2018;67(5):649-656.
McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: Treatment strategies for 163 cases of recurrent Clostridium Difficile disease. Am J Gastroenterol. 2002;97(7):1769-1775.
Hota SS, Sales V, Tomlinson G, et al. Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent Clostridium difficile Infection: an open-label, randomized controlled trial. Clin Infect Dis. 2017;64(3):265-271.
Oksi J, Aalto A, Säilä P, Partanen T, Anttila VJ, Mattila E. Real-world efficacy of bezlotoxumab for prevention of recurrent Clostridium difficile infection: a retrospective study of 46 patients in five university hospitals in Finland. Eur J Clin Microbiol Infect Dis. 2019;38(10):1947-1952.
Escudero-Sánchez R, Ruiz-Ruigómez M, Fernández-Fradejas J, et al. Real-world experience with bezlotoxumab for prevention of recurrence of Clostridioides difficile infection. J Clin Med. 2020;10(1):2.
Hengel RL, Ritter TE, Nathan RV, et al. Real-world experience of bezlotoxumab for prevention of Clostridioides difficile infection: A retrospective multicenter cohort study. Open Forum Infect Dis. 2020;7(4):ofaa097.
Cho JM, Pardi DS, Khanna S. Update on treatment of Clostridioides difficile infection. Mayo Clin Proc. 2020;95(4):758-769.
Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis. 2008;197(3):435-438.
Khanna S, Vazquez-Baeza Y, González A, et al. Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease. Microbiome. 2017;5(1):55.
Quraishi MN, Widlak M, Bhala N, et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther. 2017;46(5):479-493.
Berry P, Khanna S. Recurrent Clostridioides difficile infection: current clinical management and microbiome-based therapies. BioDrugs. Published online: Jul 26, 2023. Available from: https://link.springer.com/10.1007/s40259-023-00617-2
Neemann K, Eichele DD, Smith PW, Bociek R, Akhtari M, Freifeld A. Fecal microbiota transplantation for fulminant Clostridium difficile infection in an allogeneic stem cell transplant patient. Transpl Infect Dis. 2012;14(6):E161-E165.
Hefazi M, Patnaik MM, Hogan WJ, Litzow MR, Pardi DS, Khanna S. Safety and efficacy of fecal microbiota transplant for recurrent Clostridium difficile infection in patients with cancer treated with cytotoxic chemotherapy: a single-institution retrospective case series. Mayo Clin Proc. 2017;92(11):1617-1624.
Webb BJ, Brunner A, Ford CD, Gazdik MA, Petersen FB, Hoda D. Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2016;18(4):628-633.
Moss EL, Falconer SB, Tkachenko E, et al. Long-term taxonomic and functional divergence from donor bacterial strains following fecal microbiota transplantation in immunocompromised patients. PLOS One. 2017;12(8):e0182585.
DeFilipp Z, Bloom PP, Torres SM, et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med. 2019;381(21):2043-2050.
Kokai-Kun JF, Le C, Trout K, et al. Ribaxamase, an orally administered β-lactamase, diminishes changes to acquired antimicrobial resistance of the gut resistome in patients treated with ceftriaxone. Infect Drug Resist. 2020;13:2521-2535.
Kokai-Kun JF, Roberts T, Coughlin O, et al. Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: A double-blind, phase 2b, randomised placebo-controlled trial. Lancet Infect Dis. 2019;19(5):487-496.
De Gunzburg J, Ghozlane A, Ducher A, et al. Protection of the human gut microbiome from antibiotics. J Infect Dis. 2018;217(4):628-636.
Bruxelle JF, Péchiné S, Collignon A. Immunization strategies against clostridium difficile. In: Mastrantonio P, Rupnik M, eds. Updates on Clostridium difficile in Europe [Internet]. Springer International Publishing; 2018:197-225. Available from: http://link.springer.com/10.1007/978-3-319-72799-8_12
Leuzzi R, Adamo R, Scarselli M. Vaccines against Clostridium difficile. Hum Vaccines Immunother. 2014;10(6):1466-1477.
De Bruyn G, Saleh J, Workman D, et al. Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: A randomized Phase 2 clinical trial. Vaccine. 2016;34(19):2170-2178.
Bézay N, Ayad A, Dubischar K, et al. Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers. Vaccine. 2016;34(23):2585-2592.
Siddiqui F, O'Connor JR, Nagaro K, et al. Vaccination with parenteral toxoid B protects hamsters against lethal challenge with toxin A-negative, toxin B-positive Clostridium difficile but does not prevent colonization. J Infect Dis. 2012;205(1):128-133.
Spencer J, Leuzzi R, Buckley A, et al. Vaccination against Clostridium difficile using toxin fragments: Observations and analysis in animal models. Gut Microbes. 2014;5(2):225-232.
Maldarelli GA, Matz H, Gao S. Pilin vaccination stimulates weak antibody responses and provides no protection in a C57Bl/6 murine model of acute Clostridium difficile infection. J Vaccines Vaccin. 2016;07(03):321. Available from: https://www.omicsonline.org/open-access/pilin-vaccination-stimulates-weak-antibody-responses-and-provides-no-protection-in-a-c57bl6-murine-model-of-acute-clostridium-diff-2157-7560-1000321.php?aid=73437
Péchiné S, Bruxelle JF, Janoir C, Collignon A. Targeting Clostridium difficile surface components to develop immunotherapeutic strategies against Clostridium difficile infection. Front Microbiol. 2018;9:1009.
Tan C, Zhu F, Xiao Y, et al. Immunoinformatics approach toward the introduction of a novel multi-epitope vaccine against clostridium difficile. Front Immunol. 2022;13:887061.
Goldenberg JZ, Yap C, Lytvyn L, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017;12(12):CD006095. Available from: http://doi.wiley.com/10.1002/14651858.CD006095.pub4
Lee ACW, Ong NDS-P. Ong NDS ping. Food-Borne Bacteremic Illnesses in Febrile Neutropenic Children. Hematol Rep. 2011;3(2):e11.
Cesaro S, Chinello P, Rossi L, Zanesco L. Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii. Support Care Cancer. 2000;8(6):504-505.
Doron S, Snydman DR. Risk and safety of probiotics. Clin Infect Dis. 2015;60(2):S129-S134.
Wolf J, Kalocsai K, Fortuny C, et al. Safety and Efficacy of fidaxomicin and vancomycin in children and adolescents with Clostridioides (Clostridium) difficile infection: A phase 3, multicenter, randomized, single-blind clinical trial (SUNSHINE). Clin Infect Dis. 2020;71(10):2581-2588.
O'Gorman MA, Michaels MG, Kaplan SL, et al. Safety and pharmacokinetic study of fidaxomicin in children with Clostridium difficile-associated diarrhea: A phase 2a multicenter clinical trial. J Pediatr Infect Dis Soc. 2018;7(3):210-218.
Sferra TJ, Merta T, Neely M, et al. Double-blind, placebo-controlled study of bezlotoxumab in children receiving antibacterial treatment for Clostridioides difficile infection (MODIFY III). J Pediatr Infect Dis Soc. 2023;12(6):334-341.
Edwards PT, Thurm CW, Hall M, et al. Clostridioides difficile infection in hospitalized pediatric patients: comparisons of epidemiology, testing, and treatment from 2013 to 2019. J Pediatr. 2023;252:111-116.e1.
Lewis S, Burmeister S, Cohen S, Brazier J, Awasthi A. Failure of dietary oligofructose to prevent antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2005;21(4):469-477.
Wullt M, Hagslätt M, Louise J, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: A double-blind, placebo-controlled trial. Scand J Infect Dis. 2003;35(6-7):365-367.
McFarland LV. Update on the changing epidemiology of Clostridium difficile-associated disease. Nat Clin Pract Gastroenterol Hepatol. 2008;5(1):40-48.
Ganetsky A, Han JH, Hughes ME, et al. Oral vancomycin prophylaxis is highly effective in preventing Clostridium difficile infection in allogeneic hematopoietic cell transplant recipients. Clin Infect Dis. 2019;68(12):2003-2009.
Fishbein SRS, Hink T, Reske KA, et al. Randomized controlled trial of oral vancomycin treatment in Clostridioides difficile-colonized patients. mSphere. 2021;6(1):e00936-e01020.
Peled JU, Gomes ALC, Devlin SM, et al. Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med. 2020;382(9):822-834.
Soriano MM, Liao S, Danziger LH. Fidaxomicin: a minimally absorbed macrocyclic antibiotic for the treatment of Clostridium difficile infections. Expert Rev Anti Infect Ther. 2013;11(8):767-776.
Mullane KM, Winston DJ, Nooka A, Morris MI, Stiff P, Dugan MJ, et al. A randomized, placebo-controlled trial of fidaxomicin for prophylaxis of Clostridium difficile- associated diarrhea in adults undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2019;68(2):196-203.
Golan Y, Epstein L. Safety and efficacy of fidaxomicin in the treatment of Clostridium difficile-associated diarrhea. Ther Adv Gastroenterol. 2012;5(6):395-402.
Yamamoto T, Abe K, Anjiki H, Ishii T, Kuyama Y. Metronidazole-induced neurotoxicity developed in liver cirrhosis. J Clin Med Res. 2012;4(4):295-298. Available from: http://www.jocmr.org/index.php/JOCMR/article/view/893
Knorr JP, Javed I, Sahni N, Cankurtaran CZ, Ortiz JA. Metronidazole-induced encephalopathy in a patient with end-stage liver disease. Case Rep Hepatol. 2012;2012:1-4.
Agha A, Sehgal A, Lim MJ, et al. Peri-transplant clostridium difficile infections in patients undergoing allogeneic hematopoietic progenitor cell transplant: CDI during allogeneic stem cell transplant. Am J Hematol. 2016;91(3):291-294.
https://www.cdc.gov/cdiff/clinicians/cdi-prevention-strategies.html